Karuna Picks Up Kidney Drugs for Chance to Challenge Boehringer Ingelheim in the Brain
Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.
Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare | Feeds
Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.
Click For More Details
2023-02-03 03:14
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.